LAKE OSWEGO, Ore., May 8, 2017 /PRNewswire/ — BIOTRONIK today announced FDA approval of the company’s MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT).1 MPP will be available on new BIOTRONIK CRT defibrillator (CRT-D) systems for […]
Author: Ken Dropiewski
Boston Scientific (BSX) Snags FDA Approval for Resonate Family of High-Voltage Devices
MARLBOROUGH, Mass., May 9, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features in the Resonate devices including SmartCRT technology with Multisite Pacing […]
Murj Launches Cardiac Device Data Management Platform at Heart Rhythm Society 2017
SANTA CRUZ, Calif.–(Business Wire)–Murj, Inc., a digital health company dedicated to helping clinicians streamline care for patients with implantable cardiac devices, today announced general availability of the company’s cloud-based, HIPAA-compliant application that consolidates data from all implantable cardiac device (CIED) types and manufacturers into an elegant, robust platform that delivers […]
Abbott (ABT) Announces CE Mark And First Use Of The World’s First Smartphone Compatible Insertable Cardiac Monitor
ABBOTT PARK, Ill., May 8, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx Insertable Cardiac Monitor (ICM), the world’s first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. […]
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
MUNICH, April 27, 2017 /PRNewswire/ — ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a […]
Endologix Reports First Quarter 2017 Financial Results
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2017. “We are pleased with our progress during the quarter and our solid start to the year. Our top-line performance was driven by continued […]
Lombard Medical’s Endovascular Product Portfolio Presented at Scientific Sessions of the 39th Annual Charing Cross International Symposium
By Business Wire, May 04, 2017, 04:00:00 AM EDT OXFORDSHIRE, U.K.–(BUSINESS WIRE)– Lombard Medical, Inc. (NASDAQ:EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that its portfolio of endovascular stent graft systems, Altura® and Aorfix™, were featured in scientific presentations at the 39th annual Charing […]
Cardiovascular Systems Reports Fiscal 2017 Third-Quarter Financial Results
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (NASDAQ: CSII): Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal third quarter ended March 31, 2017. The company’s third-quarter revenues were $52.1 […]
Boston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2017
MARLBOROUGH, Mass., May 3, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of the Heart Rhythm Society in Chicago on May 10-13. Notably, the post-market approval data collected on […]
Medeon Biodesign Announces Approval to Begin CE Clinical Study
TAIPEI, Taiwan, May 2, 2017 /PRNewswire/ — Medeon Biodesign, Inc., a Taiwan publically traded medical device company, is pleased to announce today that it has received approval by the Health and Disability Ethics Committees, Ministry of Health, New Zealand to commence the CE clinical trial for the XProTM Suture-Mediated Vascular […]



